MX2017014108A - Proceso para preparar un agente anticancerigeno, (1((-(4-fluoro-2-metilo-2h-indol-5-iloxi)-6-metoxiquinolin-7-ilox i) metilo) ciclopropanamina, su forma cristalina y sus sales. - Google Patents

Proceso para preparar un agente anticancerigeno, (1((-(4-fluoro-2-metilo-2h-indol-5-iloxi)-6-metoxiquinolin-7-ilox i) metilo) ciclopropanamina, su forma cristalina y sus sales.

Info

Publication number
MX2017014108A
MX2017014108A MX2017014108A MX2017014108A MX2017014108A MX 2017014108 A MX2017014108 A MX 2017014108A MX 2017014108 A MX2017014108 A MX 2017014108A MX 2017014108 A MX2017014108 A MX 2017014108A MX 2017014108 A MX2017014108 A MX 2017014108A
Authority
MX
Mexico
Prior art keywords
yloxy
salts
methyl
cyclopropanamine
indol
Prior art date
Application number
MX2017014108A
Other languages
English (en)
Other versions
MX386321B (es
Inventor
Guoqing Paul Chen
Yan Changren
Original Assignee
Advenchen Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advenchen Pharmaceuticals Llc filed Critical Advenchen Pharmaceuticals Llc
Publication of MX2017014108A publication Critical patent/MX2017014108A/es
Publication of MX386321B publication Critical patent/MX386321B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a un nuevo procedimiento para sintetizar 1 - ((4-(4-Fluoro-2-metil-1H-indol-5-iloxi)-6-metoxiqui nolin-7-iloxi) metil) ciclopropanamina (AL3818). Se ha preparado una forma cristalina estable de A13818. Las sales y sus formas cristalinas de AL3818 también se han preparado. Las actividades anticancerígenas y optométricas de AL3818 y adicionalmente se han probado sus sales. Nuevo proceso se ha delineado en el Esquema I. (ver Fórmulas).
MX2017014108A 2015-05-04 2016-05-03 Proceso para preparar un agente anticancerigeno, (1((-(4-fluoro-2-metilo-2h-indol-5-iloxi)-6-metoxiquinolin-7-iloxi) metilo) ciclopropanamina, su forma cristalina y sus sales. MX386321B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562156734P 2015-05-04 2015-05-04
US201562205272P 2015-08-14 2015-08-14
US15/143,630 US9751859B2 (en) 2015-05-04 2016-05-02 Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts
PCT/US2016/030483 WO2016179123A1 (en) 2015-05-04 2016-05-03 Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl) cyclopropanamine, its crystalline form and its salts

Publications (2)

Publication Number Publication Date
MX2017014108A true MX2017014108A (es) 2018-03-16
MX386321B MX386321B (es) 2025-03-18

Family

ID=57218545

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014108A MX386321B (es) 2015-05-04 2016-05-03 Proceso para preparar un agente anticancerigeno, (1((-(4-fluoro-2-metilo-2h-indol-5-iloxi)-6-metoxiquinolin-7-iloxi) metilo) ciclopropanamina, su forma cristalina y sus sales.

Country Status (11)

Country Link
US (3) US9751859B2 (es)
EP (1) EP3291814B1 (es)
JP (2) JP2018515482A (es)
KR (1) KR102613409B1 (es)
CN (8) CN114129567A (es)
AU (2) AU2016257816A1 (es)
EA (1) EA201792355A1 (es)
ES (1) ES2988336T3 (es)
MX (1) MX386321B (es)
TW (1) TWI704142B (es)
WO (1) WO2016179123A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105311030B (zh) 2014-06-06 2020-03-24 正大天晴药业集团股份有限公司 用于抗肿瘤的螺取代化合物
CN105311029A (zh) 2014-06-06 2016-02-10 正大天晴药业集团股份有限公司 抗肿瘤活性的喹啉衍生物
EP3169687B1 (en) 2014-07-14 2019-01-02 Advenchen Pharmaceuticals, Nanjing Ltd. FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS
AU2015360095B2 (en) 2014-12-09 2020-02-27 Advenchen Laboratories Nanjing Ltd Quinoline derivative against non-small cell lung cancer
US9751859B2 (en) 2015-05-04 2017-09-05 Advenchen Pharmaceuticals, LLC Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts
EP3319602B1 (en) 2015-07-11 2020-02-05 Advenchen Pharmaceuticals LLC Fused quinoline compounds as pi3k/mtor inhibitors
CN107296811B (zh) * 2016-04-15 2022-12-30 正大天晴药业集团股份有限公司 一种用于治疗胃癌的喹啉衍生物
TWI771344B (zh) 2016-12-01 2022-07-21 大陸商江蘇恆瑞醫藥股份有限公司 一種ｖｅｇｆｒ抑制劑與ｐａｒｐ抑制劑聯合在製備治療胃癌的藥物中的用途
CN110650741A (zh) * 2017-05-26 2020-01-03 正大天晴药业集团股份有限公司 用于治疗结直肠癌的喹啉衍生物
CN109748902B (zh) * 2017-11-02 2020-11-06 杭州科巢生物科技有限公司 一种盐酸安罗替尼的制备方法
MX2020005659A (es) 2017-12-06 2020-08-20 Jiangsu Hengrui Medicine Co Uso de un inhibidor de parp en el tratamiento del cancer de ovario o cancer de mama resistente a la quimioterapia.
CN107970241B (zh) * 2018-01-22 2020-05-22 正大天晴药业集团股份有限公司 一种新型酪氨酸激酶抑制剂安罗替尼在制备抑制骨肉瘤的药物中的应用
CN114716410A (zh) * 2018-02-11 2022-07-08 正大天晴药业集团股份有限公司 喹啉衍生物的结晶
CN111936467B (zh) 2018-03-02 2022-02-18 正大天晴药业集团股份有限公司 作为c-Met激酶抑制剂的化合物的结晶及其制备方法和用途
CN110357856B (zh) * 2018-04-09 2021-02-26 新发药业有限公司 一种盐酸安罗替尼中间体及盐酸安罗替尼的制备方法
CN110483392A (zh) * 2018-05-14 2019-11-22 上海海和药物研究开发有限公司 合成n-保护的喹啉-7-基氧基甲基环丙基胺衍生物的方法及合成中间体
EP3816161A4 (en) * 2018-06-25 2022-03-30 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. CRYSTALLINE FACIES OF A QUINOLINE DERIVATIVE AND METHOD FOR PREPARING A CRYSTALLINE POWDER THEREOF
CN116077647B (zh) * 2018-07-18 2025-06-27 正大天晴药业集团股份有限公司 喹啉衍生物与抗体的药物组合
CN108864050B (zh) * 2018-07-25 2019-12-10 上海博璞诺科技发展有限公司 一种合成安罗替尼及其盐酸盐的方法
CN112638385B (zh) * 2018-09-18 2023-03-31 正大天晴药业集团股份有限公司 用于治疗脑肿瘤的喹啉衍生物
SG11202102682SA (en) * 2018-09-18 2021-04-29 Chia Tai Tianqing Pharmaceutical Group Co Ltd Quinoline derivative used for treating small cell lung cancer
CN118267468A (zh) 2019-01-25 2024-07-02 正大天晴药业集团股份有限公司 治疗肿瘤的联用药物组合物
CN109748904A (zh) 2019-01-31 2019-05-14 正大天晴药业集团股份有限公司 喹啉衍生物的结晶
BR112021017678A2 (pt) * 2019-03-07 2021-11-16 Advenchen Pharmaceuticals Llc Uso de catequentinibe (anlotinibe) combinando com quimioterapia padrão ou imunoterapia em ordem sequencial para o tratamento de câncer
CN113613674B (zh) 2019-03-15 2024-11-05 正大天晴药业集团股份有限公司 治疗小细胞肺癌的联用药物组合物
KR20220003560A (ko) * 2019-04-19 2022-01-10 치아타이 티안큉 파마수티컬 그룹 주식회사 유잉 육종의 치료를 위한 퀴놀린 화합물 또는 그의 약제학적으로 허용 가능한 염
CN113747897B (zh) * 2019-05-10 2024-04-02 正大天晴药业集团股份有限公司 喹啉衍生物与抗体联合治疗软组织肉瘤
US12377089B2 (en) 2019-05-10 2025-08-05 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Quinoline derivative used for soft tissue sarcoma combination therapy
JP7761490B2 (ja) * 2019-05-20 2025-10-30 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド 小細胞肺がんの併用療法用キノリン誘導体
CA3141174A1 (en) * 2019-05-23 2020-11-26 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Quinoline derivatives for treatment of head and neck cancer
CN113939315B (zh) * 2019-05-30 2024-04-02 正大天晴药业集团南京顺欣制药有限公司 治疗黑色素瘤的联用药物组合物
EP4056200A4 (en) * 2019-11-04 2024-01-10 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. MEDICINAL COMBINATION OF QUINOLINE DERIVATIVE AND MONOCLONAL PD-1 ANTIBODY
CN114929225B (zh) 2020-01-19 2024-06-28 正大天晴药业集团股份有限公司 用于治疗类风湿性关节炎的喹啉衍生物
CN113262223A (zh) * 2020-02-17 2021-08-17 上海交通大学医学院 安罗替尼及其药学上可接受的盐在制备治疗多发性骨髓瘤药物中的应用
CN115461079B (zh) * 2020-04-30 2026-06-16 正大天晴药业集团股份有限公司 用于治疗肾癌的联用药物
CN113801095B (zh) * 2020-06-12 2025-06-10 连云港润众制药有限公司 一种安罗替尼中间体的制备方法
WO2022002153A1 (zh) * 2020-06-30 2022-01-06 正大天晴药业集团股份有限公司 用于治疗肿瘤的药物
EP4197554A4 (en) * 2020-08-13 2024-09-11 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. COMBINATION DRUG FOR THE TREATMENT OF SOFT TISSUE SARCOMA
CN114470191A (zh) * 2020-10-27 2022-05-13 正大天晴药业集团股份有限公司 喹啉衍生物与pd-1单抗的药物组合
CN114432438A (zh) * 2020-11-04 2022-05-06 正大天晴药业集团股份有限公司 喹啉衍生物与pd-1单抗的药物组合
CN113116896A (zh) * 2021-04-30 2021-07-16 厦门大学附属第一医院 安罗替尼在制备急性髓系白血病干细胞杀伤药物中的应用
US20230399313A1 (en) * 2022-06-10 2023-12-14 Advenchen Pharmaceuticals, LLC Biological activities of 5-(2-(4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)ethyl)-5-azaspiro[2.4]-heptan-7-ol crystalline, phosphoric acid salt and its enantiomers
WO2024180476A1 (en) 2023-02-27 2024-09-06 Assia Chemical Industries Ltd. Solid state forms of anlotinib and process for preparation thereof
WO2025240663A1 (en) * 2024-05-15 2025-11-20 Advenchen Pharmaceuticals, LLC Using catequentinib with a specific administration regimen for cancer treatment

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
RU2478387C2 (ru) 2007-02-20 2013-04-10 Новартис Аг ИМИДАЗОХИНОЛИНЫ В КАЧЕСТВЕ ДВОЙНЫХ ИНГИБИТОРОВ ЛИПИДКИНАЗЫ И mTOR
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
US8148532B2 (en) * 2007-03-14 2012-04-03 Guoqing Paul Chen Spiro substituted compounds as angiogenesis inhibitors
EP2303890A4 (en) 2008-06-19 2012-04-11 Progenics Pharm Inc INHIBITORS OF PHOSPHATIDYLINOSITE-3-KINASE
AU2009303602B2 (en) * 2008-10-14 2012-06-14 Sunshine Lake Pharma Co., Ltd. Compounds and methods of use
IT1393351B1 (it) 2009-03-16 2012-04-20 Eos Ethical Oncology Science Spa In Forma Abbreviata Eos Spa Procedimento per la preparazione della 6-(7-((1-amminociclopropil)metossi)-6-metossichinolin-4-ilossi)-n-metil-1-naftammide e suoi intermedi di sintesi
CN103664890B (zh) * 2010-08-01 2016-10-05 正大天晴药业集团股份有限公司 喹啉衍生物的结晶及制备方法
CN103664892B (zh) * 2010-08-01 2015-09-02 正大天晴药业集团股份有限公司 喹啉衍生物的结晶
EP2780341B1 (en) 2011-11-14 2019-02-13 Chia Tai Tianqing Pharmaceutical Group Co.,Ltd Kinase modulating compounds, compositions containing the same and use thereof
WO2014032019A2 (en) * 2012-08-23 2014-02-27 Georgetown University Compounds and methods of use thereof for treating tumors
EP2945931A4 (en) 2013-01-18 2016-10-12 Advenchen Pharmaceuticals Llc PROCESS FOR THE PREPARATION OF ANTITUMOR AGENT, 6- (7 - ((1-AMINO-CYCLO-PROPYL) -METHOXY) -6-METHOXYQUINOLIN-4-YLOXY) -N-METHYL-1-NAPHTHAMIDE, AND His crystalline form
US9353123B2 (en) * 2013-02-20 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
CN104513229A (zh) 2013-09-28 2015-04-15 正大天晴药业集团股份有限公司 喹唑啉衍生物及其制备方法
CN105311030B (zh) 2014-06-06 2020-03-24 正大天晴药业集团股份有限公司 用于抗肿瘤的螺取代化合物
CN105311029A (zh) 2014-06-06 2016-02-10 正大天晴药业集团股份有限公司 抗肿瘤活性的喹啉衍生物
EP3169687B1 (en) 2014-07-14 2019-01-02 Advenchen Pharmaceuticals, Nanjing Ltd. FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS
AU2015360095B2 (en) 2014-12-09 2020-02-27 Advenchen Laboratories Nanjing Ltd Quinoline derivative against non-small cell lung cancer
US9751859B2 (en) * 2015-05-04 2017-09-05 Advenchen Pharmaceuticals, LLC Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts
EP3319602B1 (en) 2015-07-11 2020-02-05 Advenchen Pharmaceuticals LLC Fused quinoline compounds as pi3k/mtor inhibitors
CN107296811B (zh) 2016-04-15 2022-12-30 正大天晴药业集团股份有限公司 一种用于治疗胃癌的喹啉衍生物

Also Published As

Publication number Publication date
US10544125B2 (en) 2020-01-28
US20190002435A1 (en) 2019-01-03
US9751859B2 (en) 2017-09-05
TW201639830A (zh) 2016-11-16
US20160326138A1 (en) 2016-11-10
CN110172057B (zh) 2021-09-03
CN116898849A (zh) 2023-10-20
EA201792355A1 (ru) 2018-06-29
TWI704142B (zh) 2020-09-11
CN110294741A (zh) 2019-10-01
CN114129567A (zh) 2022-03-04
CN110292579A (zh) 2019-10-01
AU2020281003A1 (en) 2021-01-07
MX386321B (es) 2025-03-18
CN110292580B (zh) 2023-08-04
EP3291814B1 (en) 2024-07-10
KR102613409B1 (ko) 2023-12-14
US20180002311A1 (en) 2018-01-04
AU2016257816A1 (en) 2017-12-14
JP2021091706A (ja) 2021-06-17
CN110294741B (zh) 2021-09-03
BR112017023639A2 (pt) 2018-07-17
CN110172057A (zh) 2019-08-27
EP3291814A4 (en) 2018-12-05
EP3291814A1 (en) 2018-03-14
WO2016179123A1 (en) 2016-11-10
CN110292580A (zh) 2019-10-01
ES2988336T3 (es) 2024-11-20
JP2018515482A (ja) 2018-06-14
AU2020281003B2 (en) 2022-09-15
CN114099510A (zh) 2022-03-01
NZ737618A (en) 2024-09-27
JP7195551B2 (ja) 2022-12-26
KR20180014716A (ko) 2018-02-09
US10100034B2 (en) 2018-10-16
CN110292579B (zh) 2023-07-14
CN107771078A (zh) 2018-03-06
CA2984444A1 (en) 2016-11-10
CN107771078B (zh) 2021-11-02

Similar Documents

Publication Publication Date Title
MX386321B (es) Proceso para preparar un agente anticancerigeno, (1((-(4-fluoro-2-metilo-2h-indol-5-iloxi)-6-metoxiquinolin-7-iloxi) metilo) ciclopropanamina, su forma cristalina y sus sales.
CO2018013585A2 (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para uso en el tratamiento de transtornos neurodegenerativos.
ECSP17081744A (es) Nuevos derivados hidroxiéster,un proceso para su preparación y composiciones farmacéuticas que los contienen
ECSP14013215A (es) Compuestos novedosos
ECSP16074478A (es) Compuestos novedosos
CR20140464A (es) Compuestos de heterociclilo
UY35980A (es) Derivados de sulfamoilpirrolamida como inhibidores del hbv y composiciones farmacéuticas que los contienen
MX2020005079A (es) Derivados de aminotiazol utiles como agentes antiviricos.
SG10201805628TA (en) Deuterated heterocyclic compounds and their use as imaging agents
MX2015012414A (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
MX2018000280A (es) Oxiesteroles y metodos de uso de los mismos.
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
DOP2017000101A (es) Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina
ECSP17069696A (es) Compuestos novedosos
UY36110A (es) Inhibidores de quinasa relacionados con tropomiosina
MX2016004565A (es) Preparacion de derivados de hidroxi - bencilbenceno.
MX2020002123A (es) Sales de ribociclib y formas en estado sólido de las mismas.
CR20150456A (es) Sal abexinostate novedosos asociados en forma cristalina, procedimiento de preparación y composiciones farmacéuticas que los contienen
UY36327A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y sus usos en el tratamiento de una afección mediada por el receptor de glucocorticoides
GT201500292A (es) Formas cristalinas de inhibidores de tirosina cinasa y sus sales
UY35708A (es) Compuestos novedosos como antagonistas del receptor de ácido lisofosfatidico
UY36070A (es) Triterpenoides con actividad inhibidora de la maduración de hiv
CR20190344A (es) Activador de nrf2
UY36250A (es) Forma cristalina de sofosbuvir y proceso para su preparación
ECSP16074482A (es) Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina